Joint (JYNT) AI Stock Analysis

• Market Cap: $170.01M
• Dividend Yield: N/A
• Average Volume (3M): 60.57K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.02
• Revenue Growth: -26.14%
• EPS Growth: 23.04%
• Country: US
• Employees: 443
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Care Facilities
• EPS (TTM): -0.03
• Shares Outstanding: 15,302,772
• 10 Day Avg. Volume: 62,811
• 30 Day Avg. Volume: 60,570
• PEG Ratio: -0.35
• Price to Book (P/B): <0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 18.60
• Enterprise Value/Market Cap: 0.76
• Enterprise Value/Revenue: 0.31
• Enterprise Value/Gross Profit: 3.43
• Enterprise Value/Ebitda: 4.16
• 1Y Price Target: $17.50
• Price Target Upside: 42.16% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4

• Rating: 62 Neutral
• Price Target: $13.00 ▲(5.61%Upside)

The overall score reflects the company's strong technical momentum and positive strategic initiatives, despite financial performance challenges and valuation concerns. The strategic shift to a franchisor model and corporate governance improvements are potential drivers for future growth.

Positive Factors

Digital Strategy

The Joint is advancing its digital strategy, with increased online scheduling capabilities and the launch of its first mobile app expected, which could improve the patient experience and drive repeat visits.

Earnings Performance

Revenue from continuing operations increased by 14% to $14.4M.

Financial Health

JYNT had $25.1M in cash and no debt, and it is expected to generate positive cash flows from continuing operations.

Negative Factors

Execution Risk

Execution risks remain, as the company has yet to finalize the sale of a significant number of corporate-owned clinics.

Operational Uncertainty

The potential sale, relocation, or closure of company-owned clinics creates uncertainty.

Restructuring Challenges

The restructuring timeline remains uncertain, and near-term performance could be volatile.

Joint Business Overview & Revenue Model

Company Description

The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates in two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and regional developers. As of March 1, 2022, the company operated approximately 700 locations in the United States. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.

How the Company Makes Money

The Joint Chiropractic makes money primarily through the operation of its company-owned clinics and franchise-owned clinics. Revenue is generated from the sale of chiropractic services and membership plans that offer patients benefits such as discounted rates and unlimited visits. The company charges franchise fees and collects royalties from franchisees, which contribute to its revenue streams. Additionally, The Joint Chiropractic's business model focuses on high patient volume and low-cost service delivery, enabling profitability through economies of scale. Strategic partnerships with franchisees and a focus on expanding its network further enhance its revenue-generating capabilities.

Joint Financial Statement Overview

Summary

Joint shows a positive revenue growth trend and strong operating cash flow, but faces challenges with profitability and debt management. Improvements in cost control and leveraging its equity position could enhance overall financial stability.

Income Statement

The company's revenue has shown growth over the years, with a notable increase from 2022 to 2023. However, the company is currently operating at a net loss, with negative net profit and EBIT margins, indicating potential issues with cost management or pricing strategies.

Balance Sheet

The debt-to-equity ratio has improved, showing strong equity backing, but the company still carries significant debt, which could pose risks. Additionally, the return on equity is negative due to the net loss, impacting overall financial health.

Cash Flow

The company has demonstrated strong operating cash flow, with positive free cash flow growth. However, the high net income loss affects the free cash flow to net income ratio, suggesting potential issues with profitability conversion.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
51.90M	117.70M	101.91M	81.19M	58.68M
	Gross Profit
40.38M	107.15M	92.08M	72.68M	52.18M
	EBIT
-1.76M	-2.07M	2.90M	6.01M	5.49M
	EBITDA
2.98M	9.14M	7.89M	12.16M	8.18M
	Net Income Common Stockholders
-8.53M	-9.75M	1.18M	7.57M	13.17M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
25.05M	18.15M	9.75M	19.53M	20.55M
	Total Assets
80.42M	87.15M	91.94M	84.04M	65.73M
	Total Debt
448.29K	16.73M	26.06M	22.45M	18.48M
	Net Debt
-24.60M	-1.42M	16.31M	2.92M	-2.07M
	Total Liabilities
62.48M	62.38M	59.54M	54.48M	44.98M
	Stockholders Equity
17.92M	24.75M	32.37M	29.54M	20.75M
Cash Flow		Free Cash Flow
8.23M	9.68M	2.31M	6.85M	6.99M
	Operating Cash Flow
9.42M	14.68M	11.08M	15.23M	11.18M
	Investing Cash Flow
-631.55K	-6.19M	-20.78M	-14.14M	-4.60M
	Financing Cash Flow
-2.00M	174.12K	328.61K	-2.00M	5.60M

Joint Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 12.31
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JYNT, the sentiment is Positive. The current price of 12.31 is above the 20-day moving average (MA) of 10.32, above the 50-day MA of 10.54, and above the 200-day MA of 11.05, indicating a bullish trend. The MACD of 0.20 indicates Negative momentum. The RSI at 73.16 is Negative, neither overbought nor oversold. The STOCH value of 71.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JYNT.

Joint Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ELMD	76 Outperform	$171.75M	25.25	16.56%	―	14.85%	64.96%
UTMD	67 Neutral	$181.67M	14.84	10.59%	2.16%	-19.92%	―
BTMD	65 Neutral	$135.56M	6.01	-7.92%	―	6.44%	322.20%
JYNT	62 Neutral	$170.01M	―	-27.25%	―	-26.14%	23.04%
ARAY	61 Neutral	$163.79M	257.63	1.48%	―	8.06%	―
Sector *	54 Neutral	$5.28B	3.29	-45.38%	2.80%	16.77%	-0.08%
SGMO	43 Neutral	$120.74M	―	-262.12%	―	239.92%	79.41%

Joint Corporate Events

Joint Corp. Appoints New Director and Chair

On June 3, 2025, The Joint Corp.’s Board of Directors expanded its size and appointed Sandi Karrmann as a new director, who will also serve as Chair of the Compensation Committee. Karrmann, with extensive experience in human resources and healthcare, is expected to contribute to the company’s strategic goals of enhancing talent and culture to boost growth and profitability. Additionally, the Board approved a stock repurchase plan to buy back up to $5 million of common stock by June 2027, aiming to optimize capital structure and enhance shareholder value.

The most recent analyst rating on (JYNT) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Joint stock, see the JYNT Stock Forecast page.

Joint Confirms Board Election and Key Approvals

On May 21, 2025, Joint company held its annual meeting of stockholders where several key decisions were made. The election of seven directors to the Board was confirmed, with each nominee receiving the necessary votes to serve until the next annual meeting in 2026. Additionally, the compensation of named executive officers was approved, and the appointment of BDO USA, P.C. as the independent registered public accounting firm for the year ending December 31, 2025, was ratified.

The most recent analyst rating on (JYNT) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Joint stock, see the JYNT Stock Forecast page.

Joint Corp. Reports Q1 2025 Financial Results

On May 8, 2025, The Joint Corp. reported its financial results for the first quarter of 2025, showing a 7% increase in revenue from continuing operations to $13.1 million compared to the same period in 2024. Despite a net loss from continuing operations of $506,000, the company demonstrated economic resilience with a 5% increase in system-wide sales to $132.6 million. The company is undergoing a transition to become a pure-play franchisor, implementing new marketing and operational strategies to enhance growth and profitability. The Joint Corp. expects system-wide sales to reach between $550 million and $570 million in 2025, with new franchised clinic openings projected between 30 and 40.

Joint Corp. Amends Executive Incentive Plan for 2025

On March 10, 2025, The Joint Corp.’s Board of Directors approved an amendment to the Executive Short-Term Incentive Plan, linking executive bonuses to adjusted EBITDA performance. The company reported a 14% revenue increase for Q4 2024, with net income of $986,000 from continuing operations, marking a significant improvement from a $10.2 million loss in Q4 2023. The Joint Corp. plans to focus on refranchising and enhancing digital marketing to drive growth in 2025, with expectations of increased clinic openings and sales in 2026.